THE LATEST NEWS IN CANCER CLINICAL RESEARCH

Results from AZENT Trial have been just published on European Journal of Cancer

It’s that time of year again! It’s MOVEMBER!

MEDSIR at SEOM 2021: Update on the Recruitment Status of the DEBBRAH Study

Toripalimab joins the list of ICIs that improve efficacy when added to chemotherapy in 1L NSCLC

Dr. José Manuel Pérez Discusses Advances in Treatment Options for HER2+ Breast Cancer

We have a surprise, our new website is out!

DESTINY-BREAST03 results establish T-DXd as the standard of care for 2L metastatic breast cancer

PARSIFAL: Identifying an endocrine agent for palbociclib in endocrine sensitive ABC

PATHFINDER Study (breast)

PARSIFAL Study (breast)

Pembrolizumab may be the new standard of care for RCC with intermediate to high risk of recurrence

Spotlight: PATHFINDER Breast cancer trial

COPERNICO (Covid-19)

MEDSIR at ESMO 2021: Presentation of DEBBRAH and PATHFINDER study design

Ipilimumab-nivolumab combo as 2L does not improve survival for immunotherapy naive NSCLC

COPERNICO Results at ERS: immunotherapy combo reduces hospitalization for COVID-19 pneumonia

El Global Interview: in a post-pandemic world, clinical research needs to be made even more flexible

COVID-19 Pandemic created a cancer screening deficit in the United States

Apalutamide plus ADT improves overall survival in metastatic castration-sensitive prostate cancer

ORPHEUS: A study of the efficacy of immunotherapy for advanced cases of penile cancer

New trial to evaluate abemaciclib and endocrine therapy vs. chemotherapy in advanced breast cancer

ABIGAIL Study (breast)

Up to 30% of patients with metastatic breast cancer develop brain disease

We explore new ways to treat breast cancer with brain metastases